CLBT
The table below shows Cellebrite DI Ltd.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $173.54M | $132.17M | $102.06M | $20.58M | $36.05M | $66.51M |
| Capital expenditure | $13.22M | $8.57M | $5.23M | $6.90M | $5.11M | $6.18M |
| Investing cash flow | -$268.25M | -$149.47M | -$22.54M | -$91.23M | $45.23M | -$6.45M |
| Dividends paid | - | - | $0.00 | $0.00 | $100.00M |
Cellebrite DI Ltd. reported operating cash flow of $173.54M for fiscal year 2025. That is up 31.3% from $132.17M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow grew from $16.13M (FY 2019) to $173.54M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $10.00M |
| Stock buybacks | - | - | - | $0.00 | $0.00 | $85.00K |
| Financing cash flow | $25.05M | $20.65M | $21.77M | $13.97M | -$68.40M | -$8.59M |